Previous Article | Next Article ![]()
Infection and Immunity, December 1999, p. 6350-6357, Vol. 67, No. 12
Department of Laboratory Medicine, Lund
University, S-22362 Lund, Sweden
Received 2 August 1999/Returned for modification 20 September
1999/Accepted 30 September 1999
Strains of group B streptococcus (GBS) express surface proteins
that confer protective immunity. In particular, most strains of the
four classical capsular serotypes (Ia, Ib, II, and III) express either
of the Rib and
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Group B Streptococcal Surface Proteins as Targets
for Protective Antibodies: Identification of Two Novel Proteins in
Strains of Serotype V
proteins, two members of the same protein family.
Here, we report a study of surface proteins expressed by strains of
serotype V, which has recently emerged as an important serotype among
GBS strains causing serious disease. Two novel GBS proteins were
identified, purified, and characterized. One of these proteins,
designated Fbs, was immunologically unrelated to other GBS surface
proteins. This ~110-kDa protein was found in 15 of 49 (31%) type V
isolates but in few strains of other serotypes. The Fbs proteins
expressed by different strains showed limited variation in size. The
most common surface protein among type V strains, found in 29 of 49 (59%) isolates, was designated Rib-like, since it cross-reacted with
Rib but was not immunologically identical to Rib. Characterization of
this Rib-like protein showed that the N-terminal sequence (12 residues)
was identical to that of
, although these two proteins lacked
cross-reactivity. The biochemical and immunological properties of the
Rib-like GBS protein indicate that it is closely related to the R28
protein of Streptococcus pyogenes. Importantly, passive and
active immunization experiments with mice showed that the Fbs and
Rib-like proteins are targets for protective antibodies. These two
proteins are therefore of interest for analysis of pathogenic
mechanisms and for vaccine development.
*
Corresponding author. Mailing address: Department of
Laboratory Medicine, Lund University, Sölvegatan 23, S-22362
Lund, Sweden. Phone: 46-46-173244. Fax: 46-46-189117. E-mail:
gunnar.lindahl{at}mig.lu.se.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»